Samsung生物生物学公司与亚洲制药公司(其最大的单一客户合同)签订了1.24亿美元的交易。 Samsung Biologics secures $1.24bn deal with Asian pharmaceutical firm, its largest single-client contract.

韩国合同制造商Samsung Biologics与一家未披露的亚洲制药公司达成了12.4亿美元的交易,这是该公司最大的单一客户合同。 Samsung Biologics, a South Korean contract manufacturer, has secured a $1.24 billion deal with an undisclosed Asian pharmaceutical firm, marking its largest single-client contract. 这项协定持续到2037年12月,仅2024年就促成33亿美元以上的合同。 This agreement, lasting until December 2037, contributes to over $3.3 billion in contracts for 2024 alone. 该公司旨在增加其全球生物制药产品,并计划扩大其在日本等关键市场的存在。 The company aims to enhance its global biopharmaceutical offerings and plans to expand its presence in key markets like Japan.